Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 239-685-8 | CAS number: 15602-15-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
No acute toxicity studies with magnesium 2-ethylhexanoate are available, thus the acute toxicity will be addressed with existing data on the assessment entities magnesium and 2-ethylhexanoic acid.
Signs of acute oral or acute dermal toxicity are not expected for magnesium 2-ethylhexanoate, since the two moieties magnesium and 2-ethylhexanoic acid have not shown signs of acute oral or acute dermal toxicity in experimental testing (both LD50 > 2000mg/kg)
Key value for chemical safety assessment
Acute toxicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
Additional information
Additional information
No acute toxicity studies with magnesium 2-ethylhexanoate are available, thus the acute toxicity will be addressed with existing data on the individual moieties magnesium and 2-ethylhexanoic acid.
Magnesium
Acute oral toxicity
Humans must consume magnesium at regular intervals via diet or supplementation, mainly via oral application. “The daily recommendation for magnesium is controversial, as the literature is conflicting and varies between countries, although values of >300 mg/day are usually reported for healthy adults with adjustment for age, sex and nutritional status” (Kass et al., 2017). However, an excessive use can lead to mild side effects. When unabsorbed magnesium reaches the intestine or colon it can attract water from nearby tissue through osmosis. Therefore excessive use of magnesium and high amounts of unabsorbed magnesium in the intestine lead to diarrhoea. Side effects like diarrhoea or hypoventilation are known but mostly owing to the abuse of magnesium. For instance, Fung et al.(1995) reported the case of a 69 years old multimorbid woman who took about ca. 24 000 mg magnesium daily as an antacid. The observed serum levels increased up to 6.7 mmol/L and caused hypoventilation, but the patient recovered.
“Magnesium in foods derived from plant or animal sources has not been demonstrated to induce diarrhoea nor other adverse effects in healthy persons, probably as magnesium is bound to matrices and hence is mostly not easily bioavailable. On the other hand, easily dissociable magnesium salts (e.g. chloride or sulphate; included are compounds like magnesium oxide becoming readily dissociable after the reaction with gastric hydrochloric acid) which are present in water, many supplements and drugs, exert dose-dependent laxative effects” (EFSA scientific opinion on dietary reference values for magnesium).
Diarrhoea induced by easily dissociable magnesium salts or compounds like magnesium oxide is completely reversible within 1 to 2 days and does not represent a significant health risk in subjects with intact renal function. Poorly dissociable magnesium salts (e.g. phytates) have a lower, if any, potential to induce diarrhoea.
Acute dermal toxicity
In the absence of measured data on dermal absorption, current guidance suggests the assignment of either 10 % or 100 % default dermal absorption rates. In contrast, the currently available scientific evidence on dermal absorption of metals yields substantially lower figures, which can be summarised briefly as follows:
Measured dermal absorption values for metals or metal compounds in studies corresponding to the most recent OECD test guidelines are typically 1 % or even less. Therefore, the use of a 10 % default absorption factor is not scientifically supported for metals. This is corroborated by conclusions from previous EU risk assessments (Ni, Cd, Zn) and current metal risk assessments under REACH, which have derived dermal absorption rates of 2 % or far less (but with considerable methodical deviations from existing OECD methods) from liquid media.
However, considering that under industrial circumstances many applications involve handling of dry powders, substances and materials, and since dissolution is a key prerequisite for any percutaneous absorption, a factor 10 lower default absorption factor may be assigned to such “dry” scenarios where handling of the product does not entail use of aqueous or other liquid media. This approach was taken in the in the EU RA on zinc. A reasoning for this is described in detail elsewhere (Cherrie and Robertson, 1995), based on the argument that dermal uptake is dependent on the concentration of the material on the skin surface rather than its mass. The following default dermal absorption factors for metal cations are therefore proposed (reflective of full-shift exposure, i.e. 8 hours): From exposure to liquid/wet media: 1.0 %; From dry (dust) exposure: 0.1 %. This approach is consistent with the methodology proposed in HERAG guidance for metals (HERAG fact sheet - assessment of occupational dermal exposure and dermal absorption for metals and inorganic metal compounds; EBRC Consulting GmbH / Hannover /Germany; August 2007).
For reference list please refer to endpoint summary of the moieties.
2-ethylhexanoic acid
Acute oral toxicity
In an acute oral toxicity study 4 rats/sex/dose were dosed with 90, 722, 1445 or 2890 mg/kg bw. No mortality was observed in the 90, 722 and 1445 mg/kg bw dose groups. The test material caused mortality in rats administered a dose of 2890 mg/kg bw (4/4), and transitory weakness at lower doses in a dose-dependent manner. The LD50 was calculated to 2043 mg/kg bw.
In another acute oral toxicity study 5 rats/sex/dose have been administered 0.2, 1.6, 3.2 and 4.0 ml 2-ethylhexanoic acid/ kg bw. No substance related clinical signs nor mortality was observed at 0.2 and 1.6 ml/kg. However, 1/10 animals died. After administration of 3.2 ml/kg and 4 ml/kg apathy dyspnea abdominal position and re crusted eyes and snouts were observed. Mortality in these dose groups was 3/10, 5/10, respectively. LD 50 was estimated to be 4 mL/kg bw, being equivalent to 3640 mg/kg bw (density 0.91 g/ml). This result is supported by another study which however was poorly documented.
Acute dermal toxicity
Dermal toxicity of 2-ethylhexanoic acid was tested in an OECD 402 guideline study. Five Wistar rats/sex/dose have been exposed dermally (semi-occlusive to a limit dose of 2000 mg/kg bw 2‑ethylhexanoic acid. No mortality and no clinical symptoms beside eschar formation have been observed. LD50 dermal therefore is > 2000 mg/kg bw.
Magnesium 2-ethylhexanoate
Signs of acute oral or acute dermal toxicity are not expected for magnesium 2-ethylhexanoate, since the two moieties magnesium and 2-ethylhexanoic acid have not shown signs of acute oral or acute dermal toxicity in experimental testing (both LD50 > 2000mg/kg). Under the assumption that the constituents of magnesium 2-ethylhexanoate show their toxicological profile individually upon dissolution, the acute oral and dermal (systemic) toxicity of magnesium decanoate can be calculated using the equation given in regulation (EC) 1272/2008, Annex I, Section 3.1.3.6.1.
A study for acute toxicity via inhalation was not conducted with magnesium 2-ethylhexanoate, since it is produced and placed on the market in a form in which no inhalation hazard is anticipated, thus acute toxic effects are not likely to occur during manufacture and handling of that substance. For further information on the toxicity of the individual constituents, please refer to the relevant sections in the IUCLID and CSR.
The calculated oral and dermal LD50 for magnesium 2-ethylhexanoate is > 2000mg/kg, hence the substance is not to be classified according to regulation (EC) 1272/2008 for acute oral and dermal toxicity as well as for specific target organ toxicity, single exposure (STOT SE).
Justification for classification or non-classification
Based on in vivo oral and dermal LD50 data for the assessment entities magnesium and 2 -ethylhexanoic acid, acute toxicity estimates for magnesium 2-ethylhexanoate have been calculated resulting in LD50 values > 2000 mg/kg bw.
According to the criteria of REGULATION (EC) No 1272/2008, magnesium 2-ethylhexanoate does neither have to be classified and has no obligatory labelling requirement for acute oral or dermal toxicity nor for specific target organ toxicity after single exposure (STOT SE).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.